$USPH
U S PHYSICAL THERAPY INC /NV

2014 Q2 Form 10-Q Financial Statement

#000156459014002002 Filed on May 09, 2014

View on sec.gov

Income Statement

Concept 2014 Q2 2014 Q1 2013 Q4
Revenue $78.20M $69.77M $68.61M
YoY Change 16.95% 11.17% 9.98%
Cost Of Revenue $56.40M $53.10M $52.20M
YoY Change 14.4% 10.86% 8.98%
Gross Profit $21.80M $16.65M $16.40M
YoY Change 25.97% 12.11% 13.1%
Gross Profit Margin 27.88% 23.86% 23.9%
Selling, General & Admin $7.600M $7.100M $6.800M
YoY Change 16.92% 10.94% 11.48%
% of Gross Profit 34.86% 42.65% 41.46%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $1.440M $1.387M $1.380M
YoY Change 4.35% 2.59% 8.66%
% of Gross Profit 6.61% 8.33% 8.41%
Operating Expenses $7.600M $7.200M $6.800M
YoY Change 16.92% 12.5% 11.48%
Operating Profit $14.20M $9.514M $9.372M
YoY Change 28.4% 12.79% 12.9%
Interest Expense -$300.0K $253.0K -$100.0K
YoY Change -330.77% 87.41% 0.0%
% of Operating Profit -2.11% 2.66% -1.07%
Other Income/Expense, Net
YoY Change
Pretax Income $13.90M $9.262M $9.200M
YoY Change 31.69% 11.56% 12.2%
Income Tax $4.500M $2.939M $3.400M
% Of Pretax Income 32.37% 31.73% 36.96%
Net Earnings $6.400M $4.228M $3.861M
YoY Change 30.24% 13.63% -4.5%
Net Earnings / Revenue 8.18% 6.06% 5.63%
Basic Earnings Per Share $0.27 $0.32
Diluted Earnings Per Share $524.6K $0.27 $0.32
COMMON SHARES
Basic Shares Outstanding 12.21M 12.13M 12.10M shares
Diluted Shares Outstanding 12.14M 12.12M shares

Balance Sheet

Concept 2014 Q2 2014 Q1 2013 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $12.90M $16.80M $12.90M
YoY Change 25.24% 63.11% 10.26%
Cash & Equivalents $12.90M $16.76M $12.90M
Short-Term Investments
Other Short-Term Assets $2.700M $3.040M $4.098M
YoY Change 43.77% -22.05% -31.41%
Inventory
Prepaid Expenses
Receivables $36.20M $34.50M $32.70M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $51.80M $54.25M $49.66M
YoY Change 25.03% 21.37% 9.57%
LONG-TERM ASSETS
Property, Plant & Equipment $15.90M $14.63M $14.96M
YoY Change 15.58% 9.18% 14.94%
Goodwill $142.5M $144.0M
YoY Change 43.68%
Intangibles $15.92M $14.48M
YoY Change 19.21%
Long-Term Investments
YoY Change
Other Assets $1.100M $1.317M $1.081M
YoY Change 13.75% 31.7% 3.74%
Total Long-Term Assets $189.0M $174.4M $174.5M
YoY Change 34.04% 31.91% 38.04%
TOTAL ASSETS
Total Short-Term Assets $51.80M $54.25M $49.66M
Total Long-Term Assets $189.0M $174.4M $174.5M
Total Assets $240.8M $228.6M $224.1M
YoY Change 32.0% 29.24% 30.53%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.800M $1.400M $1.700M
YoY Change 38.46% -12.5% 0.0%
Accrued Expenses $20.10M $17.15M $20.63M
YoY Change 31.39% 46.56% 46.11%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $900.0K $775.0K $825.0K
YoY Change 12.5% 10.71% 79.74%
Total Short-Term Liabilities $22.80M $19.35M $23.17M
YoY Change 31.24% 39.17% 42.1%
LONG-TERM LIABILITIES
Long-Term Debt $45.50M $45.95M $40.65M
YoY Change 181.73% 121.98% 131.29%
Other Long-Term Liabilities $7.100M $5.031M $4.196M
YoY Change 905.67% 93.5% 84.12%
Total Long-Term Liabilities $52.60M $50.98M $44.85M
YoY Change 212.06% 118.8% 125.88%
TOTAL LIABILITIES
Total Short-Term Liabilities $22.80M $19.35M $23.17M
Total Long-Term Liabilities $52.60M $50.98M $44.85M
Total Liabilities $104.0M $71.35M $69.01M
YoY Change 195.45% 25.83% 86.25%
SHAREHOLDERS EQUITY
Retained Earnings $122.0M $119.2M
YoY Change 7.08%
Common Stock $40.58M $40.71M
YoY Change 8.19%
Preferred Stock
YoY Change
Treasury Stock (at cost) $31.63M $31.63M
YoY Change 0.0%
Treasury Stock Shares $2.215M $2.215M
Shareholders Equity $136.8M $130.9M $128.3M
YoY Change
Total Liabilities & Shareholders Equity $240.8M $228.6M $224.1M
YoY Change 32.0% 29.24% 30.53%

Cashflow Statement

Concept 2014 Q2 2014 Q1 2013 Q4
OPERATING ACTIVITIES
Net Income $6.400M $4.228M $3.861M
YoY Change 30.24% 13.63% -4.5%
Depreciation, Depletion And Amortization $1.440M $1.387M $1.380M
YoY Change 4.35% 2.59% 8.66%
Cash From Operating Activities $17.36M $3.690M $15.94M
YoY Change 9.39% -23.96% 61.01%
INVESTING ACTIVITIES
Capital Expenditures -$1.280M -$850.0K -$1.180M
YoY Change 14.29% -33.07% -7.81%
Acquisitions $125.0K
YoY Change -97.03%
Other Investing Activities -$12.72M -$2.940M -$36.46M
YoY Change 115.96% -43.02% 2414.48%
Cash From Investing Activities -$14.00M -$3.791M -$37.64M
YoY Change 99.71% -41.01% 1278.75%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -7.190M 3.964M 22.48M
YoY Change -18.76% 2019.79% -463.75%
NET CHANGE
Cash From Operating Activities 17.36M 3.690M 15.94M
Cash From Investing Activities -14.00M -3.791M -37.64M
Cash From Financing Activities -7.190M 3.964M 22.48M
Net Change In Cash -3.830M 3.863M 780.0K
YoY Change -38400.0% -378.51% -21.21%
FREE CASH FLOW
Cash From Operating Activities $17.36M $3.690M $15.94M
Capital Expenditures -$1.280M -$850.0K -$1.180M
Free Cash Flow $18.64M $4.540M $17.12M
YoY Change 9.71% -25.85% 53.13%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2013Q4 us-gaap Assets Current
AssetsCurrent
49660000
CY2014Q1 usph Furniture And Equipment Gross
FurnitureAndEquipmentGross
39472000
CY2013Q4 usph Furniture And Equipment Gross
FurnitureAndEquipmentGross
38965000
CY2014Q1 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
21701000
CY2013Q4 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
21891000
CY2014Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
61173000
CY2013Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
60856000
CY2014Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
46543000
CY2013Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
45896000
CY2014Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
14630000
CY2013Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
14960000
CY2014Q1 us-gaap Goodwill
Goodwill
142517000
CY2013Q4 us-gaap Goodwill
Goodwill
143955000
CY2014Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
15916000
CY2013Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
14479000
CY2014Q1 us-gaap Assets Current
AssetsCurrent
54254000
CY2014Q1 dei Document Type
DocumentType
10-Q
CY2014Q1 dei Amendment Flag
AmendmentFlag
false
CY2014Q1 dei Document Period End Date
DocumentPeriodEndDate
2014-03-31
CY2014Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2014
CY2014Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2014Q1 dei Trading Symbol
TradingSymbol
USPH
CY2014Q1 dei Entity Registrant Name
EntityRegistrantName
U S PHYSICAL THERAPY INC /NV
CY2014Q1 dei Entity Central Index Key
EntityCentralIndexKey
0000885978
CY2014Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2014Q1 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2014Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
12212649
CY2014Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
16761000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12898000
CY2014Q1 usph Patient Accounts Receivable
PatientAccountsReceivable
32755000
CY2013Q4 usph Patient Accounts Receivable
PatientAccountsReceivable
30820000
CY2014Q1 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
1698000
CY2013Q4 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
1844000
CY2014Q1 us-gaap Other Assets Current
OtherAssetsCurrent
3040000
CY2013Q4 us-gaap Other Assets Current
OtherAssetsCurrent
4098000
CY2014Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1317000
CY2013Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1081000
CY2014Q1 us-gaap Assets
Assets
228634000
CY2013Q4 us-gaap Assets
Assets
224135000
CY2014Q1 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
1423000
CY2013Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
1722000
CY2014Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
17147000
CY2013Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
20625000
CY2014Q1 us-gaap Long Term Debt Current
LongTermDebtCurrent
775000
CY2013Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
825000
CY2014Q1 us-gaap Liabilities Current
LiabilitiesCurrent
19345000
CY2014Q1 us-gaap Long Term Notes Payable
LongTermNotesPayable
450000
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
23172000
CY2013Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
177000
CY2014Q1 us-gaap Interest Paid Net
InterestPaidNet
345000
CY2013Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
650000
CY2014Q1 us-gaap Long Term Line Of Credit
LongTermLineOfCredit
45500000
CY2013Q4 us-gaap Long Term Line Of Credit
LongTermLineOfCredit
40000000
CY2014Q1 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
1022000
CY2013Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
996000
CY2014Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
5031000
CY2013Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
4196000
CY2014Q1 us-gaap Liabilities
Liabilities
71348000
CY2013Q4 us-gaap Liabilities
Liabilities
69014000
CY2014Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2013Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2014Q1 us-gaap Redeemable Noncontrolling Interest Equity Carrying Amount
RedeemableNoncontrollingInterestEquityCarryingAmount
2967000
CY2013Q4 us-gaap Redeemable Noncontrolling Interest Equity Carrying Amount
RedeemableNoncontrollingInterestEquityCarryingAmount
4104000
CY2014Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2013Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2014Q1 us-gaap Common Stock Value
CommonStockValue
144000
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
143000
CY2014Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
40435000
CY2013Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
40569000
CY2014Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
121970000
CY2013Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
119206000
CY2014Q1 us-gaap Treasury Stock Value
TreasuryStockValue
31628000
CY2013Q4 us-gaap Treasury Stock Value
TreasuryStockValue
31628000
CY2014Q1 us-gaap Stockholders Equity
StockholdersEquity
130921000
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
128290000
CY2014Q1 us-gaap Minority Interest
MinorityInterest
23398000
CY2013Q4 us-gaap Minority Interest
MinorityInterest
22727000
CY2014Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
154319000
CY2013Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
151017000
CY2014Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
228634000
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
224135000
CY2014Q1 usph Allowance For Doubtful Accounts Patient Accounts Receivable
AllowanceForDoubtfulAccountsPatientAccountsReceivable
1583000
CY2013Q4 usph Allowance For Doubtful Accounts Patient Accounts Receivable
AllowanceForDoubtfulAccountsPatientAccountsReceivable
1430000
CY2014Q1 us-gaap Allowance For Doubtful Accounts Premiums And Other Receivables
AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables
198000
CY2013Q4 us-gaap Allowance For Doubtful Accounts Premiums And Other Receivables
AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables
198000
CY2014Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2013Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2014Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
500000
CY2013Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
500000
CY2014Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2013Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2014Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2013Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2014Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2014Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000
CY2014Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14413102
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14315882
CY2014Q1 us-gaap Treasury Stock Shares
TreasuryStockShares
2214737
CY2013Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
2214737
CY2014Q1 us-gaap Health Care Organization Patient Service Revenue
HealthCareOrganizationPatientServiceRevenue
68397000
CY2013Q1 us-gaap Health Care Organization Patient Service Revenue
HealthCareOrganizationPatientServiceRevenue
61432000
CY2013Q1 us-gaap Profit Loss
ProfitLoss
5609000
CY2014Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
2095000
CY2013Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
1888000
CY2014Q1 us-gaap Net Income Loss
NetIncomeLoss
4228000
CY2013Q1 us-gaap Net Income Loss
NetIncomeLoss
3721000
CY2014Q1 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
0.35
CY2013Q1 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
0.32
CY2013Q1 us-gaap Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic Share
DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare
-0.01
CY2014Q1 us-gaap Income Loss Before Extraordinary Items And Cumulative Effect Of Change In Accounting Principle Per Basic Share
IncomeLossBeforeExtraordinaryItemsAndCumulativeEffectOfChangeInAccountingPrinciplePerBasicShare
0.35
CY2013Q1 us-gaap Income Loss Before Extraordinary Items And Cumulative Effect Of Change In Accounting Principle Per Basic Share
IncomeLossBeforeExtraordinaryItemsAndCumulativeEffectOfChangeInAccountingPrinciplePerBasicShare
0.31
CY2014Q1 usph Revaluation Of Redeemable Noncontrolling Interest Net Of Tax Per Share Basic
RevaluationOfRedeemableNoncontrollingInterestNetOfTaxPerShareBasic
-0.08
CY2014Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.27
CY2013Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.31
CY2014Q1 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
0.35
CY2013Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
8435000
CY2014Q1 usph Interest And Other Income Net
InterestAndOtherIncomeNet
1000
CY2013Q1 usph Interest And Other Income Net
InterestAndOtherIncomeNet
2000
CY2014Q1 us-gaap Interest Expense
InterestExpense
253000
CY2013Q1 us-gaap Interest Expense
InterestExpense
135000
CY2014Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
9262000
CY2013Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
8302000
CY2014Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2939000
CY2013Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2493000
CY2014Q1 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
6323000
CY2013Q1 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
5809000
CY2013Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
-200000
CY2014Q1 us-gaap Profit Loss
ProfitLoss
6323000
CY2013Q1 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
0.32
CY2013Q1 us-gaap Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Diluted Share
DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare
-0.01
CY2014Q1 us-gaap Income Loss Before Extraordinary Items And Cumulative Effect Of Change In Accounting Principle Per Diluted Share
IncomeLossBeforeExtraordinaryItemsAndCumulativeEffectOfChangeInAccountingPrinciplePerDilutedShare
0.35
CY2013Q1 us-gaap Income Loss Before Extraordinary Items And Cumulative Effect Of Change In Accounting Principle Per Diluted Share
IncomeLossBeforeExtraordinaryItemsAndCumulativeEffectOfChangeInAccountingPrinciplePerDilutedShare
0.31
CY2014Q1 usph Revaluation Of Redeemable Noncontrolling Interest Net Of Tax Per Share Diluted
RevaluationOfRedeemableNoncontrollingInterestNetOfTaxPerShareDiluted
-0.08
CY2014Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.27
CY2013Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.31
CY2014Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12129000
CY2014Q1 us-gaap Other Sales Revenue Net
OtherSalesRevenueNet
1370000
CY2013Q1 us-gaap Other Sales Revenue Net
OtherSalesRevenueNet
1324000
CY2014Q1 us-gaap Sales Revenue Net
SalesRevenueNet
69767000
CY2013Q1 us-gaap Sales Revenue Net
SalesRevenueNet
62756000
CY2014Q1 us-gaap Labor And Related Expense
LaborAndRelatedExpense
37942000
CY2013Q1 us-gaap Labor And Related Expense
LaborAndRelatedExpense
34059000
CY2014Q1 usph Rent Clinic Supplies Contract Labor And Other
RentClinicSuppliesContractLaborAndOther
14216000
CY2013Q1 usph Rent Clinic Supplies Contract Labor And Other
RentClinicSuppliesContractLaborAndOther
12734000
CY2014Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
950000
CY2013Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
1097000
CY2014Q1 us-gaap Restructuring Charges
RestructuringCharges
13000
CY2013Q1 us-gaap Restructuring Charges
RestructuringCharges
18000
CY2014Q1 us-gaap Costs And Expenses
CostsAndExpenses
53121000
CY2013Q1 us-gaap Costs And Expenses
CostsAndExpenses
47908000
CY2014Q1 us-gaap Gross Profit
GrossProfit
16646000
CY2013Q1 us-gaap Gross Profit
GrossProfit
14848000
CY2014Q1 usph Corporate Office Costs
CorporateOfficeCosts
7132000
CY2013Q1 usph Corporate Office Costs
CorporateOfficeCosts
6413000
CY2014Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
9514000
CY2013Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11955000
CY2014Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12144000
CY2013Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11979000
CY2014Q1 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.12
CY2013Q1 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.10
CY2014Q1 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
4228000
CY2013Q1 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
3851000
CY2013Q1 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
-130000
CY2014Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1387000
CY2013Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1352000
CY2014Q1 usph Provision For Doubtful Accounts Of Continued And Discontinued Operations
ProvisionForDoubtfulAccountsOfContinuedAndDiscontinuedOperations
950000
CY2013Q1 usph Provision For Doubtful Accounts Of Continued And Discontinued Operations
ProvisionForDoubtfulAccountsOfContinuedAndDiscontinuedOperations
1089000
CY2014Q1 us-gaap Share Based Compensation
ShareBasedCompensation
735000
CY2013Q1 us-gaap Share Based Compensation
ShareBasedCompensation
639000
CY2014Q1 usph Gain Loss On Sale Or Abandonment Of Assets Net
GainLossOnSaleOrAbandonmentOfAssetsNet
-19000
CY2013Q1 usph Gain Loss On Sale Or Abandonment Of Assets Net
GainLossOnSaleOrAbandonmentOfAssetsNet
-14000
CY2014Q1 us-gaap Excess Tax Benefit From Share Based Compensation Operating Activities
ExcessTaxBenefitFromShareBasedCompensationOperatingActivities
126000
CY2014Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
1580000
CY2013Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-219000
CY2013Q1 us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
33000
CY2014Q1 usph Increase Decrease In Patient Accounts Receivable
IncreaseDecreaseInPatientAccountsReceivable
3002000
CY2013Q1 usph Increase Decrease In Patient Accounts Receivable
IncreaseDecreaseInPatientAccountsReceivable
3429000
CY2014Q1 us-gaap Increase Decrease In Accounts Receivable And Other Operating Assets
IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets
-146000
CY2013Q1 us-gaap Increase Decrease In Accounts Receivable And Other Operating Assets
IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets
-74000
CY2014Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-735000
CY2013Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-2095000
CY2014Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-5241000
CY2013Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-2460000
CY2014Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
184000
CY2013Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
56000
CY2014Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
3690000
CY2013Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
4853000
CY2014Q1 us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
849000
CY2013Q1 us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
1270000
CY2014Q1 us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
125000
CY2013Q1 us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
4215000
CY2014Q1 usph Acquisitions Of Noncontrolling Interests
AcquisitionsOfNoncontrollingInterests
2833000
CY2013Q1 usph Acquisitions Of Noncontrolling Interests
AcquisitionsOfNoncontrollingInterests
956000
CY2014Q1 us-gaap Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
16000
CY2013Q1 us-gaap Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
14000
CY2014Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-3791000
CY2013Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-6427000
CY2014Q1 us-gaap Payments Of Dividends Minority Interest
PaymentsOfDividendsMinorityInterest
1413000
CY2013Q1 us-gaap Payments Of Dividends Minority Interest
PaymentsOfDividendsMinorityInterest
1594000
CY2013Q1 us-gaap Payments Of Dividends Common Stock
PaymentsOfDividendsCommonStock
1207000
CY2014Q1 us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
29000000
CY2013Q1 us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
30600000
CY2014Q1 us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
23500000
CY2013Q1 us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
27600000
CY2014Q1 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
250000
CY2013Q1 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
50000
CY2014Q1 us-gaap Deferred Tax Expense From Stock Options Exercised
DeferredTaxExpenseFromStockOptionsExercised
126000
CY2013Q1 us-gaap Deferred Tax Expense From Stock Options Exercised
DeferredTaxExpenseFromStockOptionsExercised
33000
CY2014Q1 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
1000
CY2013Q1 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
5000
CY2014Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3964000
CY2013Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10284000
CY2014Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
242000
CY2013Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-1387000
CY2013Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
187000
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11671000
CY2014Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
3863000
CY2014Q1 usph Period Of Federal Debt Ceiling In Connection With Deficit Reductions
PeriodOfFederalDebtCeilingInConnectionWithDeficitReductions
P10Y
CY2014Q1 us-gaap Minority Interest Decrease From Redemptions
MinorityInterestDecreaseFromRedemptions
39000
CY2014Q1 us-gaap Dividends Common Stock
DividendsCommonStock
1464000
CY2014Q1 us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
1413000
CY2013Q1 us-gaap Interest Paid Net
InterestPaidNet
119000
CY2013Q1 usph Purchase Of Business Seller Financing Portion
PurchaseOfBusinessSellerFinancingPortion
400000
CY2014Q1 usph Revaluation Of Redeemable Non Controlling Interests
RevaluationOfRedeemableNonControllingInterests
1639000
CY2014Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
1000
CY2014Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
735000
CY2014Q1 us-gaap Adjustments To Additional Paid In Capital Tax Effect From Share Based Compensation
AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation
126000
CY2014Q1 usph Revaluation Of Redeemable Noncontrolling Interests Net Of Tax
RevaluationOfRedeemableNoncontrollingInterestsNetOfTax
967000
CY2014Q1 usph Number Of Partnership In Which Interest Acquired
NumberOfPartnershipInWhichInterestAcquired
2
CY2014Q1 us-gaap Consolidation Less Than Wholly Owned Subsidiary Parent Ownership Interest Changes Purchase Of Interest By Parent
ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent
2800000
CY2013Q4 usph Payments To Acquire Businesses Consideration
PaymentsToAcquireBusinessesConsideration
47928000
CY2014Q1 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates </font></p><p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In preparing the Company&#8217;s consolidated financial statements, management makes certain estimates and assumptions, especially in relation to, but not limited to, purchase accounting, goodwill impairment, allowance for receivables, tax provision and contractual allowances, that affect the amounts reported in the consolidated financial statements and related disclosures. Actual results may differ from these estimates. </font></p></div>
CY2013Q4 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Receivables
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables
3756000
CY2014Q1 usph Medicare Service Fees Description
MedicareServiceFeesDescription
Protecting Access to Medicare Act of 2014 temporarily blocks this reduction through March 31, 2015 and replaces it with a 0.5% payment increase for services provided through December 31, 2014 and a 0% payment update from January 1, 2015 through March 31, 2015
CY2014Q1 usph Percentage Of General Partnership Interest Owned
PercentageOfGeneralPartnershipInterestOwned
0.01
CY2014Q1 usph Percentage Of Limited Partnership Interest Owned
PercentageOfLimitedPartnershipInterestOwned
0.64
CY2014Q1 usph Number Of Clinics Operated
NumberOfClinicsOperated
472
CY2014Q1 us-gaap Number Of States In Which Entity Operates
NumberOfStatesInWhichEntityOperates
43
CY2014Q1 usph Percentage Of Reduction Prevented
PercentageOfReductionPrevented
0.201
CY2013Q4 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Noncurrent Assets
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets
2283000
CY2013Q4 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Net
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
-1082000
CY2013Q4 usph Business Acquisition Purchase Price Allocation Net Tangible Asset
BusinessAcquisitionPurchasePriceAllocationNetTangibleAsset
4957000
CY2013Q4 usph Business Acquisition Purchase Price Allocation Referral Relationships
BusinessAcquisitionPurchasePriceAllocationReferralRelationships
940000
CY2013Q1 us-gaap Business Acquisition Pro Forma Earnings Per Share Diluted
BusinessAcquisitionProFormaEarningsPerShareDiluted
0.33
CY2013Q1 us-gaap Weighted Average Basic Shares Outstanding Pro Forma
WeightedAverageBasicSharesOutstandingProForma
12129000
CY2013Q3 us-gaap Business Acquisition Percentage Of Voting Interests Acquired
BusinessAcquisitionPercentageOfVotingInterestsAcquired
1.00
CY2013Q1 usph Business Combination Cost Of Acquire Entity Purchase Price
BusinessCombinationCostOfAcquireEntityPurchasePrice
5000
CY2013Q2 usph Business Combination Cost Of Acquire Entity Purchase Price
BusinessCombinationCostOfAcquireEntityPurchasePrice
95000
CY2013Q3 usph Business Combination Cost Of Acquire Entity Purchase Price
BusinessCombinationCostOfAcquireEntityPurchasePrice
130000
CY2013 us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
46628000
CY2013Q1 us-gaap Pro Forma Weighted Average Shares Outstanding Diluted
ProFormaWeightedAverageSharesOutstandingDiluted
12144000
CY2014Q1 usph Number Of Separate Transactions To Purchase Partnership Interest
NumberOfSeparateTransactionsToPurchasePartnershipInterest
3
CY2013Q4 usph Business Acquisition Cost Of Acquired Entity Debt Issued
BusinessAcquisitionCostOfAcquiredEntityDebtIssued
1300000
CY2014Q1 usph Amount Of Reductions In Federal Spending
AmountOfReductionsInFederalSpending
1200000000000
CY2014Q1 usph Reduction In Medicare Spending Percentage
ReductionInMedicareSpendingPercentage
0.02
CY2014Q1 usph Expected Reduction In Medicare Spending Percentage
ExpectedReductionInMedicareSpendingPercentage
0.02
CY2014Q1 usph Combined Physical Therapy Speech Language Pathology Expenses
CombinedPhysicalTherapySpeechLanguagePathologyExpenses
3700
CY2014Q1 usph Percentage Of Practice Expense Component Of Relative Value Unit
PercentageOfPracticeExpenseComponentOfRelativeValueUnit
1.00
CY2014Q1 usph Percentage Reduction For Service In Office Or Other Non Institutional Settings
PercentageReductionForServiceInOfficeOrOtherNonInstitutionalSettings
0.20
CY2014Q1 usph Percentage Reduction For Service In Institutional Settings
PercentageReductionForServiceInInstitutionalSettings
0.25
CY2014Q1 usph Percentage Increase In Payment Reduction In Institutional Or Non Institutional Setting
PercentageIncreaseInPaymentReductionInInstitutionalOrNonInstitutionalSetting
0.50
CY2014Q1 usph Difference Between Net Revenues And Corresponding Cash Collections Reflected Percentage Of Net Revenues
DifferenceBetweenNetRevenuesAndCorrespondingCashCollectionsReflectedPercentageOfNetRevenues
0.01
CY2014Q1 usph Maximum Difference Between Actual Aggregate Contractual Reserve Percentages As Compared To Estimated Contractual Allowance Reserve Percentage
MaximumDifferenceBetweenActualAggregateContractualReservePercentagesAsComparedToEstimatedContractualAllowanceReservePercentage
0.01
CY2014Q1 usph Minimum Difference Between Actual Aggregate Contractual Reserve Percentages Compared To Estimated Contractual Allowance Reserve Percentage
MinimumDifferenceBetweenActualAggregateContractualReservePercentagesComparedToEstimatedContractualAllowanceReservePercentage
0.01
CY2014Q1 usph Minimum Percentage Of Fair Value Reporting Unit Less Than Carrying Amount
MinimumPercentageOfFairValueReportingUnitLessThanCarryingAmount
0.50
CY2014Q1 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2013Q1 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2014Q1 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2013Q1 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2014Q1 us-gaap Interest Expense On Prepetition Liabilities Recognized In Statement Of Operations
InterestExpenseOnPrepetitionLiabilitiesRecognizedInStatementOfOperations
0
CY2013Q1 us-gaap Interest Expense On Prepetition Liabilities Recognized In Statement Of Operations
InterestExpenseOnPrepetitionLiabilitiesRecognizedInStatementOfOperations
0
CY2014Q1 usph Share Based Compensation Arrangement By Share Based Payment Share Granted To Employees Lapse In Equal Installments Description
ShareBasedCompensationArrangementByShareBasedPaymentShareGrantedToEmployeesLapseInEqualInstallmentsDescription
Shares granted to directors lapse in four equal quarterly installments and those to employees lapse in equal installments on the following four or five annual anniversaries of the date of grant
CY2014Q1 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
Prior period amounts have been reclassified to conform to current period presentation due to discontinued operations recognized in 2013
CY2014Q1 us-gaap Net Income Loss Attributable To Redeemable Noncontrolling Interest
NetIncomeLossAttributableToRedeemableNoncontrollingInterest
3261000
CY2013Q1 us-gaap Net Income Loss Attributable To Redeemable Noncontrolling Interest
NetIncomeLossAttributableToRedeemableNoncontrollingInterest
3721000
CY2014Q1 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
15000
CY2013Q1 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
24000
CY2013 usph Number Of Multi Clinic Acquisitions
NumberOfMultiClinicAcquisitions
5
CY2013Q1 us-gaap Business Acquisition Percentage Of Voting Interests Acquired
BusinessAcquisitionPercentageOfVotingInterestsAcquired
1.00
CY2013Q2 us-gaap Business Acquisition Percentage Of Voting Interests Acquired
BusinessAcquisitionPercentageOfVotingInterestsAcquired
1.00
CY2013Q4 usph Business Acquisition Purchase Price Allocation Intangible Assets Other Than Goodwill Net
BusinessAcquisitionPurchasePriceAllocationIntangibleAssetsOtherThanGoodwillNet
400000
CY2013Q4 usph Business Acquisition Purchase Price Allocation Trade Name
BusinessAcquisitionPurchasePriceAllocationTradeName
1500000
CY2013Q4 us-gaap Business Acquisition Purchase Price Allocation Goodwill Expected Tax Deductible Amount
BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount
50672000
CY2013Q4 us-gaap Business Combination Acquisition Of Less Than100 Percent Noncontrolling Interest Fair Value
BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue
10541000
CY2013Q1 us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
65461000
CY2013Q1 us-gaap Business Acquisitions Pro Forma Income Loss From Continuing Operations Before Changes In Accounting And Extraordinary Items Net Of Tax
BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax
4033000
CY2013Q1 us-gaap Business Acquisition Pro Forma Earnings Per Share Basic
BusinessAcquisitionProFormaEarningsPerShareBasic
0.33
CY2014Q1 us-gaap Payments For Repurchase Of Redeemable Noncontrolling Interest
PaymentsForRepurchaseOfRedeemableNoncontrollingInterest
2776000
CY2013Q4 us-gaap Long Term Debt
LongTermDebt
41475000
CY2013Q3 usph Facilities Previously Closed
FacilitiesPreviouslyClosed
1
CY2014Q1 usph Business Acquisition Purchase Price Allocation Net Book Value
BusinessAcquisitionPurchasePriceAllocationNetBookValue
1700000
CY2014Q1 usph Consolidation Less Than Wholly Owned Subsidiary Parent Ownership Interest Amount Changes Purchase Consideration Charge From Undistributed Earning
ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestAmountChangesPurchaseConsiderationChargeFromUndistributedEarning
1100000
CY2014Q1 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
400000
CY2014Q1 us-gaap Noncontrolling Interest In Net Income Loss Other Noncontrolling Interests Redeemable
NoncontrollingInterestInNetIncomeLossOtherNoncontrollingInterestsRedeemable
1639000
CY2014Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
45950000
CY2012Q4 usph Facilities Previously Closed
FacilitiesPreviouslyClosed
1
CY2014Q1 us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
125000
CY2014Q1 us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
0
CY2009Q1 usph Additional Estimated Repurchase Of Common Stock
AdditionalEstimatedRepurchaseOfCommonStock
340501
CY2014Q1 usph Patients And Payors Related Liability
PatientsAndPayorsRelatedLiability
1596000
CY2013Q4 usph Patients And Payors Related Liability
PatientsAndPayorsRelatedLiability
2371000
CY2014Q1 us-gaap Dividends Payable Current
DividendsPayableCurrent
1464000
CY2014Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
4218000
CY2013Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
4545000
CY2014Q1 us-gaap Long Term Debt
LongTermDebt
46725000
CY2014Q1 usph Goodwill Allocated To Specific Assets
GoodwillAllocatedToSpecificAssets
1680000
CY2014Q1 us-gaap Goodwill Purchase Accounting Adjustments
GoodwillPurchaseAccountingAdjustments
117000
CY2014Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
242000
CY2013Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
256000
CY2014Q1 usph Salaries And Related Costs Current
SalariesAndRelatedCostsCurrent
7332000
CY2013Q4 usph Salaries And Related Costs Current
SalariesAndRelatedCostsCurrent
11686000
CY2014Q1 usph Group Health Insurance Claims Current
GroupHealthInsuranceClaimsCurrent
2537000
CY2013Q4 usph Group Health Insurance Claims Current
GroupHealthInsuranceClaimsCurrent
2023000
CY2013Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
40650000
CY2013Q4 us-gaap Debt Instrument Maturity Date
DebtInstrumentMaturityDate
2018-11-30
CY2014Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
775000
CY2014Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
450000
CY2014Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
45500000
CY2008Q4 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
2250000
CY2009Q1 usph Maximum Percentage Of Repurchase Of Common Stock
MaximumPercentageOfRepurchaseOfCommonStock
0.10
CY2009Q1 usph Repurchases Of Common Stock
RepurchasesOfCommonStock
1200000
CY2009Q1 usph Bank Credit Agreement To Permit Share Repurchases Of Common Stock
BankCreditAgreementToPermitShareRepurchasesOfCommonStock
15000000
CY2009Q1 us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
859499

Files In Submission

Name View Source Status
0001564590-14-002002-index-headers.html Edgar Link pending
0001564590-14-002002-index.html Edgar Link pending
0001564590-14-002002.txt Edgar Link pending
0001564590-14-002002-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
usph-10q_20140331.htm Edgar Link pending
usph-20140331.xml Edgar Link completed
usph-20140331.xsd Edgar Link pending
usph-20140331_cal.xml Edgar Link unprocessable
usph-20140331_def.xml Edgar Link unprocessable
usph-20140331_lab.xml Edgar Link unprocessable
usph-20140331_pre.xml Edgar Link unprocessable
usph-ex31_2014033110.htm Edgar Link pending
usph-ex31_201403318.htm Edgar Link pending
usph-ex31_201403319.htm Edgar Link pending
usph-ex32_2014033111.htm Edgar Link pending